New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
08:31 EDTRGRXRegeneRx receives notice of allownace from U.S. Patent Office for new indication
RegeneRx Biopharmaceuticals has received a Notice of Allowance of a U.S. patent for the use of Thymosin beta 4, certain fragments, isoforms, derivatives and analogues to treat patients with glaucoma and elevated intraocular pressure. Glaucoma refers to a group of eye conditions that lead to damage to the optic nerve. This nerve carries visual information from the eye to the brain. In most cases, damage to the optic nerve is due to increased pressure in the eye, known as intraocular pressure. Glaucoma is the second most common cause of blindness in the United States. The patent will expire in 2026.
News For RGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
10:01 EDTRGRXRegeneRx receives Canadian patent for inhibition or reversal of skin aging
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use